Mymetics Corp (MYMX)

[Work Harder]

LVAC-HIV (vCP2438) is a preparation of live attenuated recombinant canarypox-derived virus expressing products from the HIV-1 env gp120 (subtype C ZM96 [based on HIV-1 96ZM651]), the transmembrane region of env

gp41

, gag, and protease (all subtype B HIV-1 LAI) coding sequences, and cultured in primary chicken embryo fibroblasts. The recombinant canarypox backbone vector used in ALVAC-HIV (vCP2438) was the same as that used for vCP1521 in the RV144 vaccine regimen, but the CRF01_AE gp120 insert (92TH023) was exchanged for a subtype C gp120 insert (96ZM651)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028742/

Note that they ref

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

https://www.ncbi.nlm.nih.gov/pubmed/18842730

ALVAC is Sanofi's

http://www.sanofipasteur.ca/ckfinder/userfiles/files/Fact_sheet_HIV_ALVAC_EN_tcm28-26355(1).pdf

newer vaccine called ALVAC (delivered in a disabled canarypox virus). Together, the dual vaccines provided the first evidence of significant protection in non-infected people.
Sadly, the RV144 and subsequent RV305 trials proved that the effect was short-lived, declining from a rate of 60 percent by 12 months to 31 percent by 42 months.
With that said, specific immune responses from the ALVAC vaccine proved so compelling that a new study, called the HVTN702 or Uhambo (Zulu for "Journey") trial, is currently underway in South Africa. The aim of the study is to test the efficacy of the ALVAC vaccine in preventing HIV when combined with a gp120 vaccine booster.
The phase IIb/III trial, underway since November 2016, included 5,400 non-infected men and women. The ALVAC will be delivered in an initial intramuscular injection followed by a booster 12 months later. Results are expected by 2020.

https://www.verywellhealth.com/mosaic-hiv-vaccine-sparks-hope-4173079